It is amazing, but there is a tremendous amount of research being done on resveratrol worldwide, more than any other phytochemical agent. PubMed conducted a project to find and examine all scientific papers and reports published on resveratrol. Their project found over 4,000 articles on resveratrol. These included research papers covering such areas as cardioprotective, neuroprotective, antioxidant, antidiabetic, antiplatelet, anticancer, antiviral, anti-inflammatory and changes or adjustments to the fat metabolism. Additional research found that resveratrol restricts or blocks the growth of cancer in all three known phases of chemical carcinogenesis, specifically initiation, promotion and advancement. A number of research groups also produced data developed from a number of laboratory studies. This data listed the following four diseases, cardiovascular disease, dementia, osteoarthritis and type 2 diabetes. It was also noted that the indirect effects of resveratrol on the aging process with the gene SIRT and the data gathered by these lab studies gave reason to believe the SIRT molecule is potentially able to block many of the chronic diseases considered to be the result of aging.

There is still a lack of clinical research necessary to answer questions being asked about the effective resveratrol dosage. This is very important if the dosage is really going to be necessary for accomplishing a high level of health maintenance. The Journal, “Nature” published an important pharmacological study. The research team conducted an animal study using male one-year old mice on a high-calorie diet. (This was an important distinction because the object of the study was to find the effect of resveratrol on a high-calorie diet to see if it simulated calorie restriction. The resveratrol mice data was then compared to the control group of mice receiving the same diet or a standard diet. Mice on the standard diet were lean and very healthy, whereas, the high-calorie diet made all the mice eating this diet fat. The research objective was to find out how the resveratrol affected the mice eating the high-calorie diet. ) Resveratrol
was dispensed in two different dosages, 5.2 mg/kg/day or 22.4 mg/kg/day, but data was only collected for the mice receiving 22.4 mg/kg/day.
The research team then compared data for the control group of mice and the resveratrol group. Data supported the finding that the control group of untreated mice on the same diet increased in weight even though they might be receiving resveratrol, but they did not suffer any of the typical problems associated with being fat. Collected data showed a bright benefit for the resveratrol group of mice because their survival rates were higher for the mice on the high-calorie diet; their survival rate was the same as the mice on the standard diet.

Data showed that resveratrol improved survival, but it is important to understand there were no changes in the quality of life for mice receiving the high-calorie diet. The rotarod test was used to test balance and coordination and the collected data showed that the resveratrol-treated mice on the high-calorie diet improved their motor skills at a steady rate as they aged. This improvement of motor skills continued until the mice were no longer distinguishable from the control group of mice in the standard diet. The evaluation of data at this point in the project showed resveratrol improved the following specific problems in the overfed mice and raising them to a level almost identical to the standard-diet mice: plasma albumin, fasting lamina morphology. The team was also surprised to find data showing that resveratrol blocked the effects of the high-calorie diet in 144 mice out of a total of 153 mice; this was a significant change in their metabolic pathway.

The project’s data illustrated exciting results. Scientific data supported the fact that a person could eat almost anything he likes and not suffer because they increased their weight by getting fat. This brought about a worldwide discussion about how the dosage given the mice could be given to humans in some abstracted form. The problem here is that no one has come forward with a way to establish how that could be accomplished. This points out the weakness of an animal study. This also gives good evidence that human trials are the next research step to develop a concept further.

Recent clinical trials have produced relevant data as to what is the appropriate dosage of resveratrol for humans. A human clinical trial was organized to answer this question. The research team selected a group of nineteen postmenopausal women and men. Each member of the group had an untreated condition of hypertension. The nineteen members were divided into two groups; resveratrol group and a placebo group. The resveratrol group was divided into three groups and each consumed a different a different dose of resveratrol: 30, 90 270mg or a placebo. The study was organized as a double-blind, randomized crossover comparison. Resveratrol’s plasma level was measured one hour after it was consumed. Data produced by this test on the plasma allowed them to learn how it affected the flow-mediated dilation of the brachial artery. Testing continued with increasing dosages of resveratrol. Plasma content increased in concentrations proportional to the increases in dosages. Flow-mediated dilation was increased with all the resveratrol increases, but the larger increases of dosage did not have as much impact as the opening dosage.

A similar study was examined and found to support the findings of the report above. This study also used a group nineteen patients, all of whom had type 2 diabetes. This study ran for a period of four weeks and the patients received a daily dose ten mg. The project was designed to be a double-blind, placebo-controlled, randomized clinical trial. Data collected at the end of the study showed the time it took for maximum plasma glucose after a test meal was greatly delayed by resveratrol.

Data gathered by these studies indicated that an effective human dose for a long-term usage would range from 10 to 120 mg per day. Higher doses could be used for special purposes and for a relatively short period of time.More research needs to be completed before there is solid evidence on which to base larger suggestions.
DISCLAIMER: I am not a doctor and do not give medical advice: This is a news report and cannot substitute for the advice of a medical professional.

Louisiana State University conducted a research project using two natural compounds, resveratrol and quercetin, both of which are found in red wines. The research’s objective is to find a way to improve stent performance and prevent a heart attack by opening arteries with an angioplasty procedure. An animal study was designed for the research project using rats as the test subjects.
Stents are used to open blood vessels, clogged and unclogged. Today medications are used to coat stents and this is designed to help prevent blood clots. But unfortunately, the pharmaceutical medications that are being used to coat the stents all suffer from side effects when placed in a blood vessel and this can result in the formation of blood clots in rare situations.
Louisiana State University organized the animal study to use stents coated with natural compounds to test their success against the pharmaceutical stent coatings currently being used. Resveratrol and quercetin were the natural compounds used to coat the test stents. The coated stents were then inserted into arteries in the rats and remained in the blood vessels for a period of four weeks. When the project was completed, the data was collected and several important facts were revealed. First, it was found that the stents coated with the natural compounds, resveratrol and quercetin, had stopped the narrowing of the blood vessels. Second, they found the inflammation was distinctly reduced. Marambaud, an Alzheimer’s disease researcher, stated the study looks promising. He went on to say the data is overwhelming evidence that naturaal compounds, resveratrol and quercetin, have very powerful properties. A caution was also added because this is a preliminary study and much more research needs to be done before human clinical trials can take place. Large-scale clinical trials will be needed to really find out if the coating of stents with natural compounds such as resveratrol and quercetin would be of value as a treatment for people. As this research moves forward, it will also have to explore pterostilbene as to how it can increase the benefits of resveratrol and quercetin. Pterostilbene is new and requires a lot of research some research studies have found that pterostilbene will improve the performance of resveratrol and quercetin.
DISCLAIMER: I am not a Doctor and do not give medical advice; this is a news report and cannot substitute for the advice of a medical professional.